Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid-lowering and glucose-lowering drug targets differentially modulate antipsychotic treatment efficacy in schizophrenia.

Cell reports. Medicine - 17 Mar 2026

Zhu Yunqing, Yuan Rui, Lu Zhe, Zhang Yuyanan, Kang Zhewei, Feng Xiaoyang, Zhao Guorui, Sun Junyuan, Guo Jing, Yu Tong, Yang Yang, Sun Yaoyao, Yue Weihua

Abstract excerpt

Schizophrenia is frequently comorbid with dyslipidemia and hyperglycemia. However, whether metabolic-modifying agents aggravate schizophrenia progression remains unclear. We perform a drug-target genetic association study in two independent Han Chinese schizophrenia cohorts (N = 2,111/292 for discovery/validation). Leveraging metabolic genome-wide association studies, we generate genetic risk scores (GRSs) for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Apolipoprotein C-III

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genome-Wide Association Study

Share to Hypoglycemic Agents

Share to Hypolipidemic Agents

Share to Polymorphism, Single Nucleotide

Share to Schizophrenia

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 41850236
DOI: 10.1016/j.xcrm.2026.102653
PMCID: PMC13006399

Genes

GCK
APOC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid-lowering and glucose-lowering drug targets differentially modulate antipsychotic treatment efficacy in schizophrenia.PMID 41850236Read ↗

Pharmacogenetic study of antipsychotic–induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association StudySemantic proximity Read ↗

Genome-wide association study implicates lipid pathway dysfunction in antipsychotic-induced weight gain: multi-ancestry validation.Semantic proximity Read ↗

Pharmacogenetic Study of Antipsychotic-Induced Lipid and BMI Changes in Chinese Schizophrenia Patients: A Genome-Wide Association StudySemantic proximity Read ↗

Identifying genetic contributions of 6q21 loci and PPAR pathway to antipsychotic-induced metabolic syndrome: a Sex-Stratified Multi-Omics study.Semantic proximity Read ↗

Genome Wide Association Study (GWAS) Identifies Novel Genetic Loci for Second-Generation Antipsychotics (SGA)-Induced Metabolic Syndrome (MetS).Semantic proximity Read ↗

Integrative Multiomics Analysis Identifies DKK3 as a Germline Susceptibility-Related Regulator of Risperidone Response and Metabolic Risk in Schizophrenia.Semantic proximity Read ↗

Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic TreatmentSemantic proximity Read ↗

The role of apolipoproteins as genetic biomarkers in schizophrenia: A systematic review.Semantic proximity Read ↗

Cross-population validation of European GWAS loci for metabolic syndrome in Chinese schizophrenia.Semantic proximity Read ↗

Pharmacogenetics and schizophrenia.Semantic proximity Read ↗

Pharmacogenetic intervention improves treatment outcomes in Chinese adult men with schizophreniaSemantic proximity Read ↗

Genomic and transcriptomic insights into antipsychotic-induced changes in total cholesterol and body mass index in a multi-ancestry cohort of the US veteransSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.